Robert Davis, Merck CEO
October 28, 2021 10:49 AM EDT
R&D

Ahead of clos­ing $11.5B Ac­celeron buy­out, Mer­ck is on the hunt for more deals

Nicole DeFeudis

Editor

Some­where in Ke­nil­worth, NJ, Mer­ck’s CEO Robert Davis is do­ing the hap­py dance. If all goes ac­cord­ing to plan, he’ll close out this year with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times